Infectious Disease Division, Memorial Hospital of Rhode Island, Providence, RI;
Cooper Health Systems, Camden, NJ; for the Surviving Sepsis Campaign Guidelines Committee
Dr. Opal served as board member for Arsanis, BioAegis, and Sciclone; consulted for Amplimmune; received royalties from Elsevier; and served on the data monitoring committee for Spectral, Achaogen, and Tetraphase. His institution received grant support from GlaxoSmithKline (preclinical research on genomics regulation), Asahi Kasei (Clinical coordinating center for clinical trial), and Cardeas (Clinical coordinating center for clinical trial). Dr. Dellinger disclosed that he does not have any potential conflicts of interest.